This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Amgen (AMGN) Inks Deal With Kyowa Kirin to Develop AD Treatment
by Zacks Equity Research
Amgen (AMGN) inks an agreement with Kyowa Kirin Co. to develop and commercialize the latter's KHK4083, which is being developed for the treatment of atopic dermatitis.
REGNNegative Net Change LLYNegative Net Change AMGNPositive Net Change ABBVNegative Net Change
biotechs
Omeros (OMER) Announces Data on Narsoplimab in COVID-19 Patients
by Zacks Equity Research
Omeros (OMER) announces data on critically ill COVID-19 patients treated with lead candidate, narsoplimab.
REGNNegative Net Change ZTSPositive Net Change OMERNegative Net Change RGENNegative Net Change
biotechs
CureVac (CVAC) Announces Positive Data on COVID-19 Vaccine
by Zacks Equity Research
CureVac (CVAC) announces the continuation of its COVID-19 vaccine study following the first interim analysis in 59 eligible COVID-19 cases.
PFENegative Net Change MRNANegative Net Change GSKNegative Net Change CVACNegative Net Change
biotechs pharmaceuticals
Amgen's (AMGN) KRAS Inhibitor Gets FDA Nod for Lung Cancer
by Zacks Equity Research
FDA approval of Amgen's (AMGN) Lumakras for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer is based on positive data from the phase II CodeBreaK 100 study.
RHHBYNegative Net Change NVSNegative Net Change AMGNPositive Net Change MRTXPositive Net Change
biotechs
New Strong Sell Stocks for May 28th
by Zacks Equity Research
ACET, FURY, KRYS, MRSN, and NBEV have been added to the Zacks Rank #5 (Strong Sell) List on May 28, 2021
ACETNegative Net Change NBEVNegative Net Change KRYSNegative Net Change MRSNPositive Net Change FURYPositive Net Change
biotechs consumer-discretionary gold medical
Biohaven's (BHVN) Nurtec Gets FDA Nod for Migraine Prevention
by Zacks Equity Research
The FDA approves Biohaven's (BHVN) Nurtec ODT to prevent migraine besides treating acute migraine attacks.
LLYNegative Net Change AMGNPositive Net Change ABBVNegative Net Change BHVNNegative Net Change
biotechs
Bristol Myers' (BMY) Zeposia Gets FDA Nod for Ulcerative Colitis
by Zacks Equity Research
Bristol Myers (BMY) gets FDA approval for Zeposia to treat adults with moderate-to-severe active ulcerative colitis. This marks the second indication for the drug.
ILMNNegative Net Change BMYNegative Net Change CDMOPositive Net Change
biotechs
Novartis (NVS) & Molecular Partners Initiate Study for COVID-19
by Zacks Equity Research
Novartis (NVS) initiates study for investigating its novel DARPin therapeutic candidate, ensovibep (MP0420), for the treatment of COVID-19, in collaboration with Molecular Partners.
REGNNegative Net Change NVSNegative Net Change RGENNegative Net Change CVACNegative Net Change
biotechs pharmaceuticals
Intercept (ICPT) Ocaliva's Prescribing Information Updated
by Zacks Equity Research
Intercept's (ICPT) PBC drug Ocaliva's label updated due to worsening of liver problems in some patients with cirrhosis.
NVONegative Net Change GILDNegative Net Change VKTXNegative Net Change ICPTPositive Net Change
biotechs pharmaceuticals
Vir Biotech (VIR)/Glaxo COVID-19 Drug Gets FDA Emergency Nod
by Zacks Equity Research
Glaxo (GSK)/VIR Biotech's (VIR) sotrovimab demonstrated an 85% reduction in hospitalization or death in a study evaluating it in high-risk COVID-19 patients.
REGNNegative Net Change LLYNegative Net Change GSKNegative Net Change VIRNegative Net Change
biotechs
Apellis' (APLS) Empaveli Succeeds in Treatment-Naive PNH Study
by Zacks Equity Research
Apellis' (APLS) recently approved drug, Empaveli, demonstrates superiority in hemoglobin stabilization and reduction in LDH level in treatment-naive PNH patients.
ALXNPositive Net Change ALNYNegative Net Change AKTXNegative Net Change APLSPositive Net Change
biotechs
Biotech Stock Roundup: MRNA's Vaccine Update & Pipeline Updates From REGN, BMY
by Zacks Equity Research
The biotech sector was in focus last week with pipeline and regulatory updates from Moderna (MRNA) and Regeneron (REGN), among others.
REGNNegative Net Change MRNANegative Net Change BMYNegative Net Change OMERNegative Net Change
biotechs pharmaceuticals
Moderna's (MRNA) COVID-19 Vaccine 100% Effective in Teens
by Zacks Equity Research
Moderna (MRNA) reports 100% efficacy of its COVID-19 vaccine in teenagers aged 12 to less than 18.
PFENegative Net Change MRNANegative Net Change CTLTPositive Net Change BNTXNegative Net Change
biotechs
Find Great Stocks with this New Analyst Coverage Screener
by Benjamin Rains
One way to find potential winners is to search for companies that have landed new analyst coverage recently. And the reasoning is pretty straightforward...
RMBSNegative Net Change VNDAPositive Net Change
biotechs semiconductor
Exelixis (EXEL) Reports Encouraging Data From Prostate Cancer Study
by Zacks Equity Research
Exelixis (EXEL) announces encouraging results from the cohort 6 of a phase Ib study of Cabometyx in combination with Tecentriq.
RHHBYNegative Net Change EXELPositive Net Change BMYNegative Net Change RGENNegative Net Change
biotechs pharmaceuticals
BioMarin (BMRN) Hemophilia Gene Therapy Gets EMA's Speedy Review
by Zacks Equity Research
The EMA grants accelerated assessment to BioMarin's (BMRN) request for review of valoctocogene roxaparvovec for treating severe hemophilia A.
RHHBYNegative Net Change PFENegative Net Change BMRNNegative Net Change SGMOPositive Net Change
biotechs
Do Options Traders Know Something About Eton Pharmaceuticals (ETON) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Eton Pharmaceuticals (ETON) stock based on the movements in the options market lately.
ETONNo Net Change
biotechs medical
Bristol Myers' (BMY) Opdivo-Yervoy Combo Gets Positive CHMP Opinion
by Zacks Equity Research
Bristol Myers' (BMY) Opdivo in combination with Yervoy gets positive CHMP recommendation by the EMA for an additional indication.
RHHBYNegative Net Change MRKNegative Net Change BMYNegative Net Change RGENNegative Net Change
biotechs pharmaceuticals
Regeneron (REGN)-Sanofi's Libtayo Gets Positive CHMP Opinion
by Zacks Equity Research
Regeneron (REGN) and Sanofi's (SNY) Libtayo gets positive CHMP opinion for two additional indications.
REGNNegative Net Change SNYNegative Net Change BAYRYNegative Net Change RGENNegative Net Change
biotechs pharmaceuticals
Bristol Myers (BMY) Gets FDA Nod for Another Opdivo Indication
by Zacks Equity Research
Bristol Myers (BMY) gets FDA approval for Opdivo (injection for intravenous use) for adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer.
RHHBYNegative Net Change MRKNegative Net Change BMYNegative Net Change RGENNegative Net Change
biotechs pharmaceuticals
Bear Of The Day: Allakos (ALLK)
by Brian Bolan
Missing the estimates in each of the last four quarters is never something you want to see in a stock, even a biotech like this.
biotechs
Apellis (APLS) Gets a Boost With FDA Approval of PNH Drug
by Zacks Equity Research
Approval of Apellis' (APLS) Empaveli for the treatment of paroxysmal nocturnal hemoglobinuria in the United States lends a significant boost to the company's growth prospects.
ALXNPositive Net Change ALNYNegative Net Change AKTXNegative Net Change APLSPositive Net Change
biotechs
Reata (RETA) Soars on Potential Omaveloxolone NDA Filing
by Zacks Equity Research
The FDA asks Reata (RETA) to submit a pre-NDA meeting request to discuss omaveloxolone study data and cancel its previous request for a more general Type C meeting, boosting chances of an early NDA filing.
RGENNegative Net Change BLPHPositive Net Change RETAPositive Net Change BNTXNegative Net Change
biotechs
Iovance (IOVA) Falls on Negative Lifileucel Regulatory Update
by Zacks Equity Research
Iovance (IOVA) announces delay in BLA submission for its lead pipeline candidate, lifileucel for metastatic melanoma due to potency assay issue.
RGENNegative Net Change BLPHPositive Net Change IOVAPositive Net Change BNTXNegative Net Change
biotechs
3 Biotech Stocks to Keep an Eye On Amid the Coronavirus Mayhem
by Ekta Bagri
The focus on coronavirus treatments should maintain momentum for the volatile Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BNTX, RGEN and OVID to perform well.
BIIBNegative Net Change REGNNegative Net Change GILDNegative Net Change AMGNPositive Net Change RGENNegative Net Change OVIDNegative Net Change BNTXNegative Net Change
biotechs pharmaceuticals